ACADIA PHARMACEUTICALS INC
S-1, EX-27.1, 2000-12-21
Previous: ACADIA PHARMACEUTICALS INC, S-1, EX-23.1, 2000-12-21
Next: KIRR MARBACH PARTNERS FUNDS INC, 24F-2NT/A, 2000-12-21



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS

<S>                             <C>                     <C>                     <C>
<PERIOD-TYPE>                   YEAR                   YEAR                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998             DEC-31-1999             DEC-31-2000
<PERIOD-START>                             JAN-01-1998             JAN-01-1999             JAN-01-2000
<PERIOD-END>                               DEC-31-1998             DEC-31-1999             SEP-30-2000
<EXCHANGE-RATE>                                      1                       1                       1
<CASH>                                           4,779                   3,684                  10,218
<SECURITIES>                                    12,798                   8,525                  19,266
<RECEIVABLES>                                      209                       0                       0
<ALLOWANCES>                                         0                       0                       0
<INVENTORY>                                          0                       0                       0
<CURRENT-ASSETS>                                   599                     438                     633
<PP&E>                                           3,024                   3,965                   4,984
<DEPRECIATION>                                     724                   1,456                   2,104
<TOTAL-ASSETS>                                  21,063                  15,518                  33,471
<CURRENT-LIABILITIES>                            1,446                   1,859                   2,968
<BONDS>                                          3,367                   4,432                   4,632
                           24,665                  24,665                  46,502
                                          0                       0                       0
<COMMON>                                             0                       0                       0
<OTHER-SE>                                     (8,414)                (15,437)                (20,630)
<TOTAL-LIABILITY-AND-EQUITY>                    21,063                  15,518                  33,471
<SALES>                                              0                       0                       0
<TOTAL-REVENUES>                                 1,419                   2,238                   2,768
<CGS>                                                0                       0                       0
<TOTAL-COSTS>                                        0                       0                       0
<OTHER-EXPENSES>                                 8,343                  10,083                  11,242
<LOSS-PROVISION>                                     0                       0                       0
<INTEREST-EXPENSE>                               (521)                   (400)                   (720)
<INCOME-PRETAX>                                (6,403)                 (7,445)                 (7,754)
<INCOME-TAX>                                         0                       0                       0
<INCOME-CONTINUING>                            (6,403)                 (7,445)                 (7,754)
<DISCONTINUED>                                       0                       0                       0
<EXTRAORDINARY>                                      0                       0                       0
<CHANGES>                                            0                       0                       0
<NET-INCOME>                                   (6,403)                 (7,445)                 (7,754)
<EPS-BASIC>                                     (3.12)                  (3.57)                  (3.63)
<EPS-DILUTED>                                   (3.12)                  (3.57)                  (3.63)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission